Summary
14.86 -0.33(-2.14%)05/14/2024
Acadia Pharmaceuticals Inc (ACAD)
Acadia Pharmaceuticals Inc (ACAD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.26 | -10.56 | -13.99 | -43.01 | -31.31 | -29.56 | -40.98 | 127.61 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 15.25 | |
| Open | 15.30 | |
| High | 15.53 | |
| Low | 15.11 | |
| Volume | 2,310,110 | |
| Change | 0.04 | |
| Change % | 0.26 | |
| Avg Volume (20 Days) | 1,824,974 | |
| Volume/Avg Volume (20 Days) Ratio | 1.27 | |
| 52 Week Range | 15.11 - 33.99 | |
| Price vs 52 Week High | -55.13% | |
| Price vs 52 Week Low | 0.93% | |
| Range | -0.33 | |
| Gap Up/Down | -2.20 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,520 | |
| EBIDTA | 6,069,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.4200 | |
| WallStreet Target Price | 27.39 | |
| Book Value | 2.8130 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0500 | |
| EPS Estimate Next Quarter | 0.1900 | |
| EPS Estimate Current Year | 0.6100 | |
| EPS Estimate Next Year | 1.1500 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | -0.0021 | |
| Operating Marging (TTM) | 0.0739 | |
| Return on asset (TTM) | -0.0038 | |
| Return on equity (TTM) | -0.0041 | |
| Revenue TTM | 813,806,016 | |
| Revenue per share TTM | 4.9490 | |
| Quarterly Revenue Growth (YOY) | 0.7380 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 145,494,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 26.3852 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.5412 | |
| Revenue Enterprise Value | 3.3623 | |
| EBITDA Enterprise Value | -36.0111 | |
| Shares | ||
| Shares Outstanding | 165,220,992 | |
| Shares Float | 110,357,637 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.10 | |
| Insider (%) | 0.49 | |
| Institutions (%) | 100.33 | |
05/09 16:58 EST - Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Ea.
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Ea.
05/09 07:01 EST - Zacks Investment Research
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
05/08 21:00 EST - Seeking Alpha
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Cowen Gregory Renza - RBC Capital Markets Ami Fadia - Needham & Company Yatin Suneja - Guggenheim David Hoang - Citigroup Joel Beatty - Baird Elaine Kim - Cantor Jose Lora - Citizens JMP Ash Verma - UBS Marc Goodman - Leerink Sumanth Kulkarni - Canaccord Genuity Uy Ear - Mizuho Operator Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Cowen Gregory Renza - RBC Capital Markets Ami Fadia - Needham & Company Yatin Suneja - Guggenheim David Hoang - Citigroup Joel Beatty - Baird Elaine Kim - Cantor Jose Lora - Citizens JMP Ash Verma - UBS Marc Goodman - Leerink Sumanth Kulkarni - Canaccord Genuity Uy Ear - Mizuho Operator Good day, everyone, and thank you for standing by. Welcome to the ACADIA Pharmaceuticals First Quarter 2024 Financial Results and Operating Overview Conference Call.
05/08 18:16 EST - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago.
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to loss of $0.27 per share a year ago.
05/06 11:41 EST - Zacks Investment Research
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
04/29 16:16 EST - Business Wire
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year's recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year. “Families affected by Rett syndro.
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year's recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year. “Families affected by Rett syndro.
04/11 14:10 EST - InvestorPlace
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
3 Pharma Stocks to Sell in April Before They Crash & Burn
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures.
03/12 15:20 EST - Investopedia
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
03/12 12:11 EST - Zacks Investment Research
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
03/12 10:46 EST - InvestorPlace
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
03/12 09:30 EST - InvestorPlace
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
03/11 17:01 EST - Market Watch
Acadia Pharma's stock falls 15% after failed drug trial
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
Acadia Pharma's stock falls 15% after failed drug trial
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
02/28 10:15 EST - Zacks Investment Research
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues.
02/27 18:21 EST - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to loss of $0.26 per share a year ago.
02/20 11:06 EST - Zacks Investment Research
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/15 11:35 EST - Reuters
Culper Research takes short position in Acadia Pharma
Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.
Culper Research takes short position in Acadia Pharma
Culper Research said on Thursday it has taken a short position on Acadia Pharmaceuticals' stock.
01/22 22:42 EST - Seeking Alpha
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
01/04 12:47 EST - Zacks Investment Research
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
12/29 14:17 EST - Zacks Investment Research
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
12/21 16:05 EST - Business Wire
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentat.
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 9:00 a.m. Pacific Time, followed by a question and answer session. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentat.